Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 22821 - 22840 out of 495978 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Australia | (L01FX13) enfortumab vedotin | Padcev 20 mg powder for injection, 1 vial | Powder for I.V. infusion 20 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
| Australia | (L01FX13) enfortumab vedotin | Padcev 30 mg powder for injection, 1 vial | Powder for I.V. infusion 30 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
| Australia | (L01FX13) enfortumab vedotin | Padcev 30 mg powder for injection, 1 vial | Powder for I.V. infusion 30 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | AstellasPharmaAustraliaPtyLtd |
| Australia | (L01FX17) sacituzumab govitecan | Trodelvy 180 mg powder for injection, 1 vial | Powder for injection 180 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciencesPtyLimited |
| Australia | (L01FX17) sacituzumab govitecan | Trodelvy 180 mg powder for injection, 1 vial | Powder for injection 180 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciencesPtyLimited |
| Australia | (L01FX17) sacituzumab govitecan | Trodelvy 180 mg powder for injection, 1 vial | Powder for injection 180 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciencesPtyLimited |
| Australia | (L01FX17) sacituzumab govitecan | Trodelvy 180 mg powder for injection, 1 vial | Powder for injection 180 mg, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Breast Neoplasms;Triple Negative Breast Neoplasms | GileadSciencesPtyLimited |
| Australia | (L01FX18) amivantamab | Rybrevant 350 mg/7 mL injection, 7 mL vial | Solution concentrate for I.V. infusion 350 mg in 7 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | Janssen-CilagPtyLtd |
| Australia | (L01FX18) amivantamab | Rybrevant 350 mg/7 mL injection, 7 mL vial | Solution concentrate for I.V. infusion 350 mg in 7 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | Janssen-CilagPtyLtd |
| Australia | (L01FX18) amivantamab | Rybrevant 350 mg/7 mL injection, 7 mL vial | Solution concentrate for I.V. infusion 350 mg in 7 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | Janssen-CilagPtyLtd |
| Australia | (L01FX18) amivantamab | Rybrevant 350 mg/7 mL injection, 7 mL vial | Solution concentrate for I.V. infusion 350 mg in 7 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | Janssen-CilagPtyLtd |
| Australia | (L01FX27) epcoritamab | Epkinly 4 mg/0.8 mL injection, 0.8 mL vial | Solution concentrate for subcutaneous injection 4 mg in 0.8 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Lymphoma, Large B-Cell, Diffuse | AbbViePtyLtd |
| Australia | (L01FX27) epcoritamab | Epkinly 48 mg/0.8 mL injection, 0.8 mL vial | Solution for subcutaneous injection 48 mg in 0.8 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Lymphoma, Large B-Cell, Diffuse | AbbViePtyLtd |
| Australia | (L01FX27) epcoritamab | Epkinly 48 mg/0.8 mL injection, 0.8 mL vial | Solution for subcutaneous injection 48 mg in 0.8 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Lymphoma, Large B-Cell, Diffuse | AbbViePtyLtd |
| Australia | (L01FY02) nivolumab and relatlimab | Opdualag injection, 20 mL vial | Solution concentrate for I.V. infusion containing 240 mg nivolumab and 80 mg relatlimab in 20 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FY02) nivolumab and relatlimab | Opdualag injection, 20 mL vial | Solution concentrate for I.V. infusion containing 240 mg nivolumab and 80 mg relatlimab in 20 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FY02) nivolumab and relatlimab | Opdualag injection, 20 mL vial | Solution concentrate for I.V. infusion containing 240 mg nivolumab and 80 mg relatlimab in 20 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FY02) nivolumab and relatlimab | Opdualag injection, 20 mL vial | Solution concentrate for I.V. infusion containing 240 mg nivolumab and 80 mg relatlimab in 20 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FY02) nivolumab and relatlimab | Opdualag injection, 20 mL vial | Solution concentrate for I.V. infusion containing 240 mg nivolumab and 80 mg relatlimab in 20 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma | Bristol-MyersSquibbAustraliaPtyLtd |
| Australia | (L01FY02) nivolumab and relatlimab | Opdualag injection, 20 mL vial | Solution concentrate for I.V. infusion containing 240 mg nivolumab and 80 mg relatlimab in 20 mL, 1 pcs | Retail price without vat |
$0-0 |
$0-0 |
Melanoma | Bristol-MyersSquibbAustraliaPtyLtd |
Pages
